Cell proliferation rates and fibronectin arrangement as parameters for biocompatibility evaluation of dental metal alloys in vitro.
A short-term (72-96 hours) biocompatibility evaluation in vitro of four single phase dental metal alloys was conducted by determining cell proliferation rates correlated to the organization of the extracellular matrix protein fibronectin in human fibroblast cultures. Immunocytochemical methods were performed to detect both cell proliferation rates by 5-bromodeoxyuridine (BrdU) incorporation, and fibronectin arrangement, i.e., diffuse in the extracellular matrix, organized in fibrils or in focal adhesions. We showed that cell proliferation rates were related to fibronectin expression. In particular, a higher percentage of cells in the S-phase were related to a predominance of fibronectin organized both in fibrils and in focal adhesions. The alloy with the highest Au content seemed the most biocompatible among those tested, since it behaved in a very similar manner to the controls. On the contrary, fibroblasts exposed to the alloy with the highest percentage of Ag had the most different behavior as compared to the controls. We can assume that a correlation exists between fibronectin organization and the percentage of BrdU-positive cells and that these parameters are varying with the different metal composition of the alloys. The observation of fibronectin arrangement together with cell proliferation rates could be considered a useful tool to determine the biocompatibility of these biomaterials.
Grill
V
V
Department of Human Morphology, University of Trieste, Italy.
Sandrucci
M A
MA
Di Lenarda
R
R
Dorigo
E
E
Narducci
P
P
Martelli
A M
AM
Bareggi
R
R
D001672:Biocompatible Materials / Q000737:chemistry / Q000494:pharmacology; D001681:Biological Assay; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003722:Dental Alloys / Q000737:chemistry / Q000494:pharmacology*; D005347:Fibroblasts / Q000737:chemistry / Q000166:cytology / Q000187:drug effects; D005353:Fibronectins / Q000737:chemistry / Q000187:drug effects*; D006047:Gold Alloys / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D008422:Materials Testing; D016196:S Phase / Q000187:drug effects; D012834:Silver / Q000737:chemistry / Q000494:pharmacology
D001672:Biocompatible Materials; D003722:Dental Alloys; D005353:Fibronectins; D006047:Gold Alloys; D012834:Silver; D001973:Bromodeoxyuridine